AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer¿s Disease and Elevated Amyloid (A45 Trial)

Project: Federal Funding Agencies

Project Details

StatusFinished
Effective start/end date9/30/195/31/22